KROS (Keros Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by KROS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-20 | Annita Tanini | Corp. Controller & VP, Finance | Sell | — | — |
| 2026-08-20 | Charles W. Newton | Director | Sell | — | — |
| 2026-08-20 | Lorena Raquel Lerner | Chief Scientific Officer | Sell | — | — |
| 2026-08-20 | Esther Cho | Chief Legal Officer | Sell | — | — |
| 2026-08-19 | JEAN JACQUES BIENAIME | Director | Buy | — | — |
| 2026-07-17 | JEAN JACQUES BIENAIME | Director | Buy | — | — |
| 2026-07-06 | Anne Prener | Director | A | — | — |
| 2026-06-17 | JEAN JACQUES BIENAIME | Director | Buy | — | — |
| 2026-06-15 | Charles W. Newton | Director | Sell | — | — |
| 2026-06-08 | Nima Farzan | Director | Sell | — | — |
| 2026-06-08 | Julius Knowles | Director | Sell | — | — |
| 2026-06-05 | JEAN JACQUES BIENAIME | Director | A | — | — |
| 2026-06-05 | Alpna Seth | Director | A | — | — |
| 2026-06-05 | MARY ANN GRAY | Director | A | — | — |
| 2026-06-05 | Nima Farzan | Director | A | — | — |
| 2026-06-05 | Julius Knowles | Director | A | — | — |
| 2026-06-05 | Alpna Seth | Director | Sell | — | — |
| 2026-05-19 | JEAN JACQUES BIENAIME | Director | Buy | — | — |
| 2026-04-17 | JEAN JACQUES BIENAIME | Director | Buy | — | — |
| 2026-04-06 | Jasbir Seehra | CHIEF EXECUTIVE OFFICER | M | — | — |
| 2026-03-27 | Esther Cho | Chief Legal Officer | A | — | — |
| 2026-03-11 | JEAN JACQUES BIENAIME | Director | Buy | — | — |
| 2026-03-11 | Charles W. Newton | Director | A | — | — |
| 2026-02-26 | Lorena Raquel Lerner | Chief Scientific Officer | A | — | — |
| 2026-02-26 | Esther Cho | Chief Legal Officer | A | — | — |
| 2026-02-26 | Keith Regnante | CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-02-26 | Jasbir Seehra | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2026-02-20 | Jasbir Seehra | CHIEF EXECUTIVE OFFICER | Sell | — | — |
| 2026-02-20 | Keith Regnante | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2026-02-20 | Lorena Raquel Lerner | Chief Science Officer | Sell | — | — |
| 2026-02-20 | Esther Cho | SVP, General Counsel | Sell | — | — |
| 2026-01-09 | Jasbir Seehra | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-12-18 | Julius Knowles | Director | D | — | — |
| 2025-12-18 | CARL L GORDON | Director | D | — | — |
| 2025-12-18 | OrbiMed Capital GP VII LLC | Director | D | — | — |
| 2025-10-17 | Pontifax (Cayman) IV L.P. | 10%+ Owner | Sell | — | — |
| 2025-10-15 | Daniel Schneeberger | 10%+ Owner | Sell | — | — |
| 2025-09-05 | Jasbir Seehra | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-06-24 | Daniel Schneeberger | 10%+ Owner | X | — | — |
| 2025-06-12 | ADAR1 Capital Management GP, LLC | 10%+ Owner | E | — | — |
| 2025-06-11 | Tomer Kariv | Director | — | — | — |
| 2025-06-11 | Ran Nussbaum | Director | — | — | — |
| 2025-06-06 | Alpna Seth | Director | A | — | — |
| 2025-06-06 | JEAN JACQUES BIENAIME | Director | A | — | — |
| 2025-06-06 | Ran Nussbaum | Director | A | — | — |
| 2025-06-06 | Nima Farzan | Director | A | — | — |
| 2025-06-06 | Julius Knowles | Director | A | — | — |
| 2025-06-06 | CARL L GORDON | Director | A | — | — |
| 2025-06-06 | MARY ANN GRAY | Director | A | — | — |
| 2025-06-06 | Tomer Kariv | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,288,151 | — |
| — | 10%+ Owner | 2,288,151 | — |
| — | Director | 2,036,140 | — |
| — | 10%+ Owner | 1,725,565 | — |
| — | Director | 764,405 | — |
| — | CHIEF EXECUTIVE OFFICER | 440,708 | — |
| — | Director | 160,512 | — |
| — | Director | 160,512 | — |
| — | Director | 119,522 | — |
| — | Director | 113,191 | — |
| — | Chief Scientific Officer | 95,100 | — |
| — | Chief Operating Officer | 60,000 | — |
| — | Corp. Controller & VP, Finance | 45,144 | — |
| — | Director | 45,057 | — |
| — | Chief Medical Officer | 44,000 | — |
| — | CHIEF FINANCIAL OFFICER | 39,261 | — |
| — | Chief Legal Officer | 35,770 | — |
| — | Chief Scientific Officer | 27,559 | — |
| — | Director | 19,592 | — |
| — | Director | 13,786 | — |
| — | Director | 12,392 | — |
| — | Director | 12,114 | — |
| — | Director | 9,767 | — |
| — | Director | 9,767 | — |
| — | Chief Medical Officer | 347 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KROS quote page; the site-wide leaderboard is on the insider transactions hub.